Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
出版年份 2023 全文链接
标题
Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
作者
关键词
-
出版物
Cancers
Volume 15, Issue 2, Pages 375
出版商
MDPI AG
发表日期
2023-01-06
DOI
10.3390/cancers15020375
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Association of Antithyroid Antibodies in Checkpoint Inhibitor–Associated Thyroid Immune–Related Adverse Events
- (2022) Christopher A Muir et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study
- (2022) Shinobu Takayasu et al. Scientific Reports
- Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1
- (2022) John A. McCulloch et al. NATURE MEDICINE
- Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma
- (2022) Hodaka Yamada et al. BMC Endocrine Disorders
- Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors
- (2022) Hidefumi Inaba et al. Endocrinology and Metabolism
- Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature
- (2021) V. Lo Preiato et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy
- (2021) C. Luongo et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
- (2021) Heidar J. Albandar et al. Cancers
- Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome
- (2021) Keitaro Kanie et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Endocrine complications of immunotherapies: a review
- (2021) Rosie Hattersley et al. CLINICAL MEDICINE
- Thyroid immune-related adverse events following immune checkpoint inhibitor treatment
- (2021) Christopher A Muir et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors
- (2021) Tomoko Kobayashi et al. Journal for ImmunoTherapy of Cancer
- A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab
- (2021) Sonya K. Kedzior et al. American Journal of Case Reports
- Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study
- (2021) Nežka Hribernik et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
- (2021) Bryan J. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study
- (2021) Wenhui Liu et al. Frontiers in Immunology
- Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study
- (2020) Norio Okada et al. BRITISH JOURNAL OF CANCER
- Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors
- (2020) Chiaki Kurimoto et al. CANCER SCIENCE
- Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
- (2020) Xiaoxiang Zhou et al. BMC Medicine
- Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor–induced secondary adrenal insufficiency
- (2020) Seiichi Yano et al. EUROPEAN JOURNAL OF CANCER
- Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
- (2020) Eli P. Darnell et al. Current Oncology Reports
- Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH
- (2020) M. S. Siddiqui et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Immune-related adverse events of checkpoint inhibitors
- (2020) Manuel Ramos-Casals et al. Nature Reviews Disease Primers
- The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors
- (2020) Evangelos Koustas et al. Biomolecules
- Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab
- (2020) Ganessan Kichenadasse et al. Journal of the National Comprehensive Cancer Network
- Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy
- (2020) L. Brilli et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer
- (2020) Bairavi Shankar et al. JAMA Oncology
- A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
- (2019) Jeroen de Filette et al. HORMONE AND METABOLIC RESEARCH
- BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI PD-1 INDUCED THYROID DYSFUNCTION
- (2019) Rena M. Pollack et al. Endocrine Practice
- A comprehensive meta-analysis of endocrine immune-related adverse events of immune checkpoint inhibitors and outcomes in head and neck cancer and lung cancer.
- (2019) Cristiane Jeyce Gomes-Lima et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative analysis of human leucocyte antigen between idiopathic and anti‐PD‐1 antibody induced isolated adrenocorticotropic hormone deficiency: A pilot study
- (2019) Hidefumi Inaba et al. CLINICAL ENDOCRINOLOGY
- Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
- (2019) Salahaldin A. Tahir et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- New insight in endocrine-related adverse events associated to immune checkpoint blockade
- (2019) Giusy Elia et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Biomarker definitions and their applications
- (2018) Robert M Califf EXPERIMENTAL BIOLOGY AND MEDICINE
- Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti‐PD‐1 Therapy
- (2018) Sagun Parakh et al. ONCOLOGIST
- Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis
- (2018) Sunita M. C. De Sousa et al. Pituitary
- Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions
- (2018) Yifan Wang et al. Frontiers in Pharmacology
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Association of anti-thyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
- (2018) Shiro Kimbara et al. CANCER SCIENCE
- Endocrine toxicity of cancer immunotherapy targeting immune checkpoints
- (2018) Lee-Shing Chang et al. ENDOCRINE REVIEWS
- Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
- (2018) Yiyi Yan et al. Frontiers in Immunology
- Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype
- (2018) Lucien Marchand et al. ACTA DIABETOLOGICA
- Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
- (2018) Emma C. de Moel et al. Cancer Immunology Research
- Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
- (2018) Yukihiro Toi et al. JAMA Oncology
- Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies
- (2017) Alice Bernard-Tessier et al. EUROPEAN JOURNAL OF CANCER
- Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non–Small Cell Lung Cancer
- (2017) Yuko Usui et al. Journal of Thoracic Oncology
- Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
- (2017) Adam Diehl et al. Oncotarget
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar et al. Frontiers in Pharmacology
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
- (2016) Elisa González-Rodríguez et al. ONCOLOGIST
- Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy
- (2016) Masahide Okamoto et al. Journal of Diabetes Investigation
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- What are biomarkers?
- (2010) Kyle Strimbu et al. Current Opinion in HIV and AIDS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started